Montelukast Accord (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Accord, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed to treat asthma, allergic rhinitis, and to prevent exercise‑induced bronchoconstriction in adults and children. The medication works by blocking cysteinyl leukotriene receptors in the airways, reducing inflammation and narrowing of the bronchial tubes.

GNH USA supplies Montelukast Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and health‑care institutions worldwide. The company provides reliable logistics and regulatory support to ensure timely delivery.

Montelukast, a leukotriene receptor antagonist, is used to manage respiratory conditions driven by leukotriene‑mediated inflammation.

- Asthma: improves long‑term control and reduces frequency of asthma exacerbations in patients requiring maintenance therapy. - Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing during or after physical activity, allowing better exercise tolerance.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Angioedema or swelling of the face, lips or tongue - Mood changes, including depression or suicidal thoughts - Severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

- Assess asthma control before initiation: confirm that patient’s disease is stable on current therapy. - Monitor for neuropsychiatric events: watch for mood swings, depression or suicidal ideation. - Use caution in hepatic impairment: dose adjustment may be required in patients with liver dysfunction. - Avoid use in patients with known hypersensitivity: discontinue if allergic reaction occurs. - Review concomitant medications for interactions: especially CYP inducers or inhibitors. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Montelukast can interact with other medicines, affecting its plasma levels or therapeutic response.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce montelukast exposure. - Concurrent use with phenobarbital: accelerates metabolism leading to loss of efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, fluconazole): may increase montelukast concentrations. - Oral contraceptives: monitor for potential reduced contraceptive effectiveness. - Warfarin: observe INR values as montelukast may alter anticoagulant response.